Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.

Journal of neuro-oncology - 1 Aug 2012

Ahmadi Rezvan, Stockhammer Florian, Becker Natalia, Hohlen Katarina, Misch Martin, Christians Arne, Dictus Christine, Herold-Mende Christel, Capper David, Unterberg Andreas, von Deimling Andreas, Wick Wolfgang, Hartmann Christian

Abstract excerpt

Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been identified in approximately 70-80 % of astrocytomas and oligodendrogliomas of WHO grades II and III, and in secondary glioblastomas. In addition, a low incidence of IDH2 mutations has been detected in these tumors, and the occurence of IDH1 and IDH2 mutations is mutually exclusive. For patients with anaplastic gliomas and glioblastomas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Prognosis

Share to Survival Rate

Share to World Health Organization

Source

Identifiers

PMID: 22528790
DOI: 10.1007/s11060-012-0863-y

Genes

IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.PMID 22528790Read ↗

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.Semantic proximity Read ↗

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.Semantic proximity Read ↗

A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.Semantic proximity Read ↗

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas.Semantic proximity Read ↗

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.Semantic proximity Read ↗

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.Semantic proximity Read ↗

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.Semantic proximity Read ↗

Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.Semantic proximity Read ↗

IDH1 mutation of gliomas with long-term survival analysis.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.Semantic proximity Read ↗

Molecular markers in low-grade gliomas: predictive or prognostic?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.